Successful therapeutic use of rituximab in refractory membranous glomerulonephritis

Clinical Nephrology

Volumn 66, Issue 1, 2006, Pages 54-57

  Cobo Caso, M ^a   Hernandez D ^a   Rodriguez, C ^a   Perez Tamajon L ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

Membranous glomerulonephritis; Nephrotic syndrome; Rituximab

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATORVASTATIN; CHLORAMBUCIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; IRBESARTAN; LISINOPRIL; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; SERUM ALBUMIN; STEROID;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; DIZZINESS; DRUG USE; FOLLOW UP; HUMAN; HYPOTENSION; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PANCYTOPENIA; PROTEINURIA; REMISSION; RESPIRATORY TRACT INFECTION; TREATMENT DURATION;

EID: 33745903383     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp66054     Document Type: Article

References (11)

1. Cohen CD, Calvaresi N, Armelloni S, Schmid H, Henger A, Ott U, Rastaldi MP, Kretzler M. CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol. 2005; 18: 328-333.
2. Johnson PWM, Glennie MJ. Rituximab: mechanisms and applications. Br J Cancer. 2001; 85: 1619-1623.
3. Kerjaschki D, Farquhar MG. Immunocytochemical localization of the Heymann nephritis antigen (Gp330) in glomerular epithelial cells of normal Lewis rats. J Exp Med. 1983; 157: 667-686.
4. Leandro MJ, Edwards JC, Cambridge J. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002; 61: 883-888.
5. Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G. Immunosuppresive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis. 2004; 44: 385-401.
6. Ponticelli C, Zucchelli P, Passerini P et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med. 1989; 320: 8-13.
7. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet. 2002; 360: 923-924.
8. Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, Cavallo R, Alpa M, Costanzo P, Giachino O, Mazzucco LG, Sena LM. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant. 2004; 19: 3054-3061.
9. Rossi P, Demoux AL, Granel B, Bagneres D, Bonin-Guillaume S, Frances Y. Anti-CD20 monoclonal antibody for the treatment of refractory autoimmune hemolytic: anaemia associated with idiopathic membranous nephropathy. Rheumatology (Oxford). 2005; 44: 403-405.
10. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol. 2003; 14: 1851-1857.
11. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an opel-label trial. Arthritis Rheum. 2005; 52: 501-513.